Interrogating functional integration between injected pluripotent stem cell-derived cells and surrogate cardiac tissue

Hannah Song, Charles Yoon, Steven J. Kattman, Jana Dengler, Stéphane Massé, Thushaanthini Thavaratnam, Mena Gewarges, Kumaraswamy Nanthakumar, Michael Rubart-von der Lohe, Gordon M. Keller, Milica Radisic, Peter W. Zandstra

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Myocardial infarction resulting in irreversible loss of cardiomyocytes (CMs) remains a leading cause of heart failure. Although cell transplantation hasmodestly improved cardiac function, major challenges including increasing cell survival, engraftment, and functional integration with host tissue, remain. Embryonic stem cells (ESCs), which can be differentiated into cardiac progenitors (CPs) and CMs, represent a candidate cell source for cardiac cell therapy. However, it is not known what specific cell type or condition is themost appropriate for transplantation. This problem is exasperated by the lack of efficient and predictive strategies to screen the large numbers of parameters that may impact cell transplantation. We used a cardiac tissuemodel, engineered heart tissue (EHT), and quantitative molecular and electrophysiological analyses, to test transplantation conditions and specific cell populations for their potential to functionally integratewith the host tissue. In this study, we validated our analytical platform using contractile mouse neonatal CMs (nCMs) and noncontractile cardiac fibroblasts (cFBs), and screened for the integration potential of ESC-derived CMs and CPs (ESC-CMs and -CPs). Consistent with previous in vivo studies, cFB injection interferedwith electrical signal propagation, whereas injected nCMs improved tissue function. Purified bioreactor-generated ESC-CMs exhibited a diminished capacity for electrophysiological integration; a result correlated with lower (compared with nCMs) connexin 43 expression. ESC-CPs, however, appeared able to appropriately mature and integrate into EHT, enhancing the amplitude of tissue contraction. Our results support the use of EHTas amodel system to accelerate development of cardiac cell therapy strategies.

Original languageEnglish
Pages (from-to)3329-3334
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume107
Issue number8
DOIs
StatePublished - Feb 23 2010

Fingerprint

Pluripotent Stem Cells
Cardiac Myocytes
Embryonic Stem Cells
Cell Transplantation
Cell- and Tissue-Based Therapy
Transplantation
Connexin 43
Bioreactors
Cell Survival
Heart Failure
Fibroblasts
Myocardial Infarction
Injections
Population

Keywords

  • Cardiac progenitor
  • Cell therapy
  • Engineered heart tissue
  • Myocardial infarction
  • Regenerative medicine

ASJC Scopus subject areas

  • General

Cite this

Interrogating functional integration between injected pluripotent stem cell-derived cells and surrogate cardiac tissue. / Song, Hannah; Yoon, Charles; Kattman, Steven J.; Dengler, Jana; Massé, Stéphane; Thavaratnam, Thushaanthini; Gewarges, Mena; Nanthakumar, Kumaraswamy; Rubart-von der Lohe, Michael; Keller, Gordon M.; Radisic, Milica; Zandstra, Peter W.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 8, 23.02.2010, p. 3329-3334.

Research output: Contribution to journalArticle

Song, H, Yoon, C, Kattman, SJ, Dengler, J, Massé, S, Thavaratnam, T, Gewarges, M, Nanthakumar, K, Rubart-von der Lohe, M, Keller, GM, Radisic, M & Zandstra, PW 2010, 'Interrogating functional integration between injected pluripotent stem cell-derived cells and surrogate cardiac tissue', Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 8, pp. 3329-3334. https://doi.org/10.1073/pnas.0905729106
Song, Hannah ; Yoon, Charles ; Kattman, Steven J. ; Dengler, Jana ; Massé, Stéphane ; Thavaratnam, Thushaanthini ; Gewarges, Mena ; Nanthakumar, Kumaraswamy ; Rubart-von der Lohe, Michael ; Keller, Gordon M. ; Radisic, Milica ; Zandstra, Peter W. / Interrogating functional integration between injected pluripotent stem cell-derived cells and surrogate cardiac tissue. In: Proceedings of the National Academy of Sciences of the United States of America. 2010 ; Vol. 107, No. 8. pp. 3329-3334.
@article{11740ee3465744bfb0012e1a754bb8d2,
title = "Interrogating functional integration between injected pluripotent stem cell-derived cells and surrogate cardiac tissue",
abstract = "Myocardial infarction resulting in irreversible loss of cardiomyocytes (CMs) remains a leading cause of heart failure. Although cell transplantation hasmodestly improved cardiac function, major challenges including increasing cell survival, engraftment, and functional integration with host tissue, remain. Embryonic stem cells (ESCs), which can be differentiated into cardiac progenitors (CPs) and CMs, represent a candidate cell source for cardiac cell therapy. However, it is not known what specific cell type or condition is themost appropriate for transplantation. This problem is exasperated by the lack of efficient and predictive strategies to screen the large numbers of parameters that may impact cell transplantation. We used a cardiac tissuemodel, engineered heart tissue (EHT), and quantitative molecular and electrophysiological analyses, to test transplantation conditions and specific cell populations for their potential to functionally integratewith the host tissue. In this study, we validated our analytical platform using contractile mouse neonatal CMs (nCMs) and noncontractile cardiac fibroblasts (cFBs), and screened for the integration potential of ESC-derived CMs and CPs (ESC-CMs and -CPs). Consistent with previous in vivo studies, cFB injection interferedwith electrical signal propagation, whereas injected nCMs improved tissue function. Purified bioreactor-generated ESC-CMs exhibited a diminished capacity for electrophysiological integration; a result correlated with lower (compared with nCMs) connexin 43 expression. ESC-CPs, however, appeared able to appropriately mature and integrate into EHT, enhancing the amplitude of tissue contraction. Our results support the use of EHTas amodel system to accelerate development of cardiac cell therapy strategies.",
keywords = "Cardiac progenitor, Cell therapy, Engineered heart tissue, Myocardial infarction, Regenerative medicine",
author = "Hannah Song and Charles Yoon and Kattman, {Steven J.} and Jana Dengler and St{\'e}phane Mass{\'e} and Thushaanthini Thavaratnam and Mena Gewarges and Kumaraswamy Nanthakumar and {Rubart-von der Lohe}, Michael and Keller, {Gordon M.} and Milica Radisic and Zandstra, {Peter W.}",
year = "2010",
month = "2",
day = "23",
doi = "10.1073/pnas.0905729106",
language = "English",
volume = "107",
pages = "3329--3334",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "8",

}

TY - JOUR

T1 - Interrogating functional integration between injected pluripotent stem cell-derived cells and surrogate cardiac tissue

AU - Song, Hannah

AU - Yoon, Charles

AU - Kattman, Steven J.

AU - Dengler, Jana

AU - Massé, Stéphane

AU - Thavaratnam, Thushaanthini

AU - Gewarges, Mena

AU - Nanthakumar, Kumaraswamy

AU - Rubart-von der Lohe, Michael

AU - Keller, Gordon M.

AU - Radisic, Milica

AU - Zandstra, Peter W.

PY - 2010/2/23

Y1 - 2010/2/23

N2 - Myocardial infarction resulting in irreversible loss of cardiomyocytes (CMs) remains a leading cause of heart failure. Although cell transplantation hasmodestly improved cardiac function, major challenges including increasing cell survival, engraftment, and functional integration with host tissue, remain. Embryonic stem cells (ESCs), which can be differentiated into cardiac progenitors (CPs) and CMs, represent a candidate cell source for cardiac cell therapy. However, it is not known what specific cell type or condition is themost appropriate for transplantation. This problem is exasperated by the lack of efficient and predictive strategies to screen the large numbers of parameters that may impact cell transplantation. We used a cardiac tissuemodel, engineered heart tissue (EHT), and quantitative molecular and electrophysiological analyses, to test transplantation conditions and specific cell populations for their potential to functionally integratewith the host tissue. In this study, we validated our analytical platform using contractile mouse neonatal CMs (nCMs) and noncontractile cardiac fibroblasts (cFBs), and screened for the integration potential of ESC-derived CMs and CPs (ESC-CMs and -CPs). Consistent with previous in vivo studies, cFB injection interferedwith electrical signal propagation, whereas injected nCMs improved tissue function. Purified bioreactor-generated ESC-CMs exhibited a diminished capacity for electrophysiological integration; a result correlated with lower (compared with nCMs) connexin 43 expression. ESC-CPs, however, appeared able to appropriately mature and integrate into EHT, enhancing the amplitude of tissue contraction. Our results support the use of EHTas amodel system to accelerate development of cardiac cell therapy strategies.

AB - Myocardial infarction resulting in irreversible loss of cardiomyocytes (CMs) remains a leading cause of heart failure. Although cell transplantation hasmodestly improved cardiac function, major challenges including increasing cell survival, engraftment, and functional integration with host tissue, remain. Embryonic stem cells (ESCs), which can be differentiated into cardiac progenitors (CPs) and CMs, represent a candidate cell source for cardiac cell therapy. However, it is not known what specific cell type or condition is themost appropriate for transplantation. This problem is exasperated by the lack of efficient and predictive strategies to screen the large numbers of parameters that may impact cell transplantation. We used a cardiac tissuemodel, engineered heart tissue (EHT), and quantitative molecular and electrophysiological analyses, to test transplantation conditions and specific cell populations for their potential to functionally integratewith the host tissue. In this study, we validated our analytical platform using contractile mouse neonatal CMs (nCMs) and noncontractile cardiac fibroblasts (cFBs), and screened for the integration potential of ESC-derived CMs and CPs (ESC-CMs and -CPs). Consistent with previous in vivo studies, cFB injection interferedwith electrical signal propagation, whereas injected nCMs improved tissue function. Purified bioreactor-generated ESC-CMs exhibited a diminished capacity for electrophysiological integration; a result correlated with lower (compared with nCMs) connexin 43 expression. ESC-CPs, however, appeared able to appropriately mature and integrate into EHT, enhancing the amplitude of tissue contraction. Our results support the use of EHTas amodel system to accelerate development of cardiac cell therapy strategies.

KW - Cardiac progenitor

KW - Cell therapy

KW - Engineered heart tissue

KW - Myocardial infarction

KW - Regenerative medicine

UR - http://www.scopus.com/inward/record.url?scp=77649248002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649248002&partnerID=8YFLogxK

U2 - 10.1073/pnas.0905729106

DO - 10.1073/pnas.0905729106

M3 - Article

VL - 107

SP - 3329

EP - 3334

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 8

ER -